190 related articles for article (PubMed ID: 12149644)
1. Her2/neu induces all-trans retinoic acid (ATRA) resistance in breast cancer cells.
Tari AM; Lim SJ; Hung MC; Esteva FJ; Lopez-Berestein G
Oncogene; 2002 Aug; 21(34):5224-32. PubMed ID: 12149644
[TBL] [Abstract][Full Text] [Related]
2. The HER2/Grb2/Akt pathway regulates the DNA binding activity of AP-1 in breast cancer cells.
Mendoza-Gamboa E; Siwak DR; Tari AM
Oncol Rep; 2004 Oct; 12(4):903-8. PubMed ID: 15375520
[TBL] [Abstract][Full Text] [Related]
3. HER2/neu uses Akt to suppress retinoic acid response element binding activity in MDA-MB-453 breast cancer cells.
Siwak DR; Mendoza-Gamboa E; Tari AM
Int J Oncol; 2003 Dec; 23(6):1739-45. PubMed ID: 14612949
[TBL] [Abstract][Full Text] [Related]
4. N-(4-hydroxyphenyl)-retinamide selectively increases All-TRANS retinoic acid inhibitory effects in HER2/NEU-overexpressing breast cancer cells.
Lim SJ; Gutiérrez-Puente Y; Tari AM
Tumour Biol; 2002; 23(5):279-86. PubMed ID: 12595744
[TBL] [Abstract][Full Text] [Related]
5. Grb2 downregulation leads to Akt inactivation in heregulin-stimulated and ErbB2-overexpressing breast cancer cells.
Lim SJ; Lopez-Berestein G; Hung MC; Lupu R; Tari AM
Oncogene; 2000 Dec; 19(54):6271-6. PubMed ID: 11175341
[TBL] [Abstract][Full Text] [Related]
6. Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors.
Chan CT; Metz MZ; Kane SE
Breast Cancer Res Treat; 2005 May; 91(2):187-201. PubMed ID: 15868447
[TBL] [Abstract][Full Text] [Related]
7. Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action.
Yakes FM; Chinratanalab W; Ritter CA; King W; Seelig S; Arteaga CL
Cancer Res; 2002 Jul; 62(14):4132-41. PubMed ID: 12124352
[TBL] [Abstract][Full Text] [Related]
8. Cellular and molecular determinants of all-trans retinoic acid sensitivity in breast cancer: Luminal phenotype and RARα expression.
Centritto F; Paroni G; Bolis M; Garattini SK; Kurosaki M; Barzago MM; Zanetti A; Fisher JN; Scott MF; Pattini L; Lupi M; Ubezio P; Piccotti F; Zambelli A; Rizzo P; Gianni' M; Fratelli M; Terao M; Garattini E
EMBO Mol Med; 2015 Jul; 7(7):950-72. PubMed ID: 25888236
[TBL] [Abstract][Full Text] [Related]
9. Preventive efficacy of receptor class selective retinoids on HER-2/neu oncogene expressing preneoplastic human mammary epithelial cells.
Jinno H; Steiner MG; Nason-Burchenal K; Osborne MP; Telang NT
Int J Oncol; 2002 Jul; 21(1):127-34. PubMed ID: 12063559
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
Moulder SL; Yakes FM; Muthuswamy SK; Bianco R; Simpson JF; Arteaga CL
Cancer Res; 2001 Dec; 61(24):8887-95. PubMed ID: 11751413
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
[TBL] [Abstract][Full Text] [Related]
12. Apigenin induces apoptosis through proteasomal degradation of HER2/neu in HER2/neu-overexpressing breast cancer cells via the phosphatidylinositol 3-kinase/Akt-dependent pathway.
Way TD; Kao MC; Lin JK
J Biol Chem; 2004 Feb; 279(6):4479-89. PubMed ID: 14602723
[TBL] [Abstract][Full Text] [Related]
13. Heregulin regulation of Akt/protein kinase B in breast cancer cells.
Liu W; Li J; Roth RA
Biochem Biophys Res Commun; 1999 Aug; 261(3):897-903. PubMed ID: 10441522
[TBL] [Abstract][Full Text] [Related]
14. Resistance to tamoxifen-induced apoptosis is associated with direct interaction between Her2/neu and cell membrane estrogen receptor in breast cancer.
Chung YL; Sheu ML; Yang SC; Lin CH; Yen SH
Int J Cancer; 2002 Jan; 97(3):306-12. PubMed ID: 11774281
[TBL] [Abstract][Full Text] [Related]
15. Induction of retinoid resistance in breast cancer cells by overexpression of cJun.
Yang L; Kim HT; Munoz-Medellin D; Reddy P; Brown PH
Cancer Res; 1997 Oct; 57(20):4652-61. PubMed ID: 9377582
[TBL] [Abstract][Full Text] [Related]
16. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling.
She QB; Solit D; Basso A; Moasser MM
Clin Cancer Res; 2003 Oct; 9(12):4340-6. PubMed ID: 14555504
[TBL] [Abstract][Full Text] [Related]
17. Overcoming trastuzumab resistance in HER2-overexpressing breast cancer cells by using a novel celecoxib-derived phosphoinositide-dependent kinase-1 inhibitor.
Tseng PH; Wang YC; Weng SC; Weng JR; Chen CS; Brueggemeier RW; Shapiro CL; Chen CY; Dunn SE; Pollak M; Chen CS
Mol Pharmacol; 2006 Nov; 70(5):1534-41. PubMed ID: 16887935
[TBL] [Abstract][Full Text] [Related]
18. HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression.
Laughner E; Taghavi P; Chiles K; Mahon PC; Semenza GL
Mol Cell Biol; 2001 Jun; 21(12):3995-4004. PubMed ID: 11359907
[TBL] [Abstract][Full Text] [Related]
19. HER2/neu reduces the apoptotic effects of N-(4-hydroxyphenyl)retinamide (4-HPR) in breast cancer cells by decreasing nitric oxide production.
Simeone AM; Broemeling LD; Rosenblum J; Tari AM
Oncogene; 2003 Oct; 22(43):6739-47. PubMed ID: 14555987
[TBL] [Abstract][Full Text] [Related]
20. A new selective AKT pharmacological inhibitor reduces resistance to chemotherapeutic drugs, TRAIL, all-trans-retinoic acid, and ionizing radiation of human leukemia cells.
Martelli AM; Tazzari PL; Tabellini G; Bortul R; Billi AM; Manzoli L; Ruggeri A; Conte R; Cocco L
Leukemia; 2003 Sep; 17(9):1794-805. PubMed ID: 12970779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]